Zydus Lifesciences revenue and financials

ZYDUSLIFE · NSE · INR

₹1,153.00−0.56%−₹6.50

Close · October 7, 2026

In the fiscal year ended March 2026, Zydus Lifesciences reported revenue of ₹267.2B (+18.37% year over year). Net income was ₹50.4B, a net margin of 18.9%.

Annual revenue · 2026: ₹267.2B

₹168.78B2023
₹190.22B2024
₹225.74B2025
₹267.2B2026

Fiscal year ending in March. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +18.37%; FY to Mar 2026 vs FY to Mar 2025
Net income growth: +11.37%; FY to Mar 2026 vs FY to Mar 2025
Net margin: 18.9%; FY to Mar 2025: 20.0%

Financial data

Amounts in millions of INR; per-share values in INR; shares in millions.

Balance sheet · Quarterly
Item	Q1 2026	Q1 2025
Total assets	524,066	372,017
Current assets	199,061	170,461
Cash and equivalents	8,552	8,268
Short-term investments	41,159	48,148
Inventory	56,281	39,440
Net property, plant and equipment	107,297	75,597
Goodwill	75,427	52,421
Other intangible assets	98,652	32,236
Long-term investments	11,666	11,431
Current liabilities	157,119	90,416
Accounts payable	28,451	22,807
Long-term debt	31,880	0.0
Total debt	124,960	32,132
Total liabilities	228,244	108,433
Total equity (incl. minority)	295,822	263,584
Retained earnings	284,879	245,616
Minority interest	24,708	24,053